Q2 2024 EPS Estimates for Sanofi Boosted by Leerink Partnrs (NASDAQ:SNY)

Sanofi (NASDAQ:SNYFree Report) – Analysts at Leerink Partnrs increased their Q2 2024 EPS estimates for Sanofi in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $0.93 for the quarter, up from their prior estimate of $0.92. The consensus estimate for Sanofi’s current full-year earnings is $4.25 per share. Leerink Partnrs also issued estimates for Sanofi’s Q3 2024 earnings at $1.36 EPS.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. cut shares of Sanofi from an “overweight” rating to a “neutral” rating in a research report on Tuesday, December 5th. Stifel Nicolaus downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, StockNews.com upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $57.50.

Check Out Our Latest Research Report on SNY

Sanofi Price Performance

Shares of SNY stock opened at $46.92 on Thursday. The firm has a fifty day moving average of $49.27 and a two-hundred day moving average of $50.71. The firm has a market cap of $118.69 billion, a P/E ratio of 19.88, a P/E/G ratio of 2.24 and a beta of 0.63. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.28 and a quick ratio of 0.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SNY. Avantax Advisory Services Inc. raised its position in shares of Sanofi by 1.3% during the 4th quarter. Avantax Advisory Services Inc. now owns 22,934 shares of the company’s stock worth $1,141,000 after buying an additional 291 shares in the last quarter. Boston Partners boosted its stake in Sanofi by 1.9% during the 4th quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after purchasing an additional 245,682 shares in the last quarter. Forum Financial Management LP increased its position in shares of Sanofi by 17.0% in the fourth quarter. Forum Financial Management LP now owns 35,639 shares of the company’s stock worth $1,772,000 after acquiring an additional 5,168 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Sanofi by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 315,021 shares of the company’s stock valued at $15,666,000 after acquiring an additional 7,211 shares in the last quarter. Finally, Johnson Investment Counsel Inc. boosted its stake in Sanofi by 47.1% in the 4th quarter. Johnson Investment Counsel Inc. now owns 10,969 shares of the company’s stock worth $545,000 after purchasing an additional 3,514 shares during the period. Institutional investors own 10.06% of the company’s stock.

Sanofi Company Profile

(Get Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Earnings History and Estimates for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.